James F. Howard Jr., MD, professor in the UNC Department of Neurology, was principal investigator of the phase 3 trial for the experimental drug efgartigimod, developed by Belgian pharmaceutical company Argenx.

Over 800 scientists from across the United States and overseas convened virtually for a joint Duke/UNC Alzheimer’s Disease Symposium on May 27.